Kai Bachmann1, Maximillian Bockhorn1, Oliver Mann1, Florian Gebauer1, Marco Blessmann2, Jakob Robert Izbicki1, Katharina Grupp3,4. 1. General, Visceral and Thoracic Surgery Department and Clinic, University Medical Center Hamburg-Eppendorf, 20251, Hamburg, Germany. 2. Department of Plastic, Reconstructive and Aesthetic Surgery, University Medical Center Hamburg-Eppendorf, 20251, Hamburg, Germany. 3. General, Visceral and Thoracic Surgery Department and Clinic, University Medical Center Hamburg-Eppendorf, 20251, Hamburg, Germany. k.grupp@uke.de. 4. Department of Plastic, Reconstructive and Aesthetic Surgery, University Medical Center Hamburg-Eppendorf, 20251, Hamburg, Germany. k.grupp@uke.de.
Abstract
INTRODUCTION: The heterotrimeric Sec61α translocon complex is topological located in the membrane of the endoplasmic reticulum (ER) and allows protein transport and calcium across the membrane. Recently, aberrant expression of Sec proteins was linked to carcinogenesis and prognosis of patients. MATERIALS AND METHODS: Here, we analysed the role of Sec61α in esophageal cancer, and we analysed Sec61α staining on a tissue microarray containing more than 600 esophageal cancer specimens by immunohistochemistry. RESULTS: Sec61α staining was always strong in benign esophagus, but was only found in 5% of interpretable esophageal adenocarcinomas (EACs) and 14.5% of squamous cell carcinomas (ESCCs). Reduced Sec61α staining was not strongly linked to tumor phenotype in both subgroups of esophageal cancers and was unrelated to clinical outcome of patients (EACs: p = 0.8051 and ESCCs: p = 0.2751). CONCLUSIONS: Thus, Sec61α measurement has not an additional prognostic benefit for the patients.
INTRODUCTION: The heterotrimeric Sec61α translocon complex is topological located in the membrane of the endoplasmic reticulum (ER) and allows protein transport and calcium across the membrane. Recently, aberrant expression of Sec proteins was linked to carcinogenesis and prognosis of patients. MATERIALS AND METHODS: Here, we analysed the role of Sec61α in esophageal cancer, and we analysed Sec61α staining on a tissue microarray containing more than 600 esophageal cancer specimens by immunohistochemistry. RESULTS: Sec61α staining was always strong in benign esophagus, but was only found in 5% of interpretable esophageal adenocarcinomas (EACs) and 14.5% of squamous cell carcinomas (ESCCs). Reduced Sec61α staining was not strongly linked to tumor phenotype in both subgroups of esophageal cancers and was unrelated to clinical outcome of patients (EACs: p = 0.8051 and ESCCs: p = 0.2751). CONCLUSIONS: Thus, Sec61α measurement has not an additional prognostic benefit for the patients.
Authors: Bert Van den Berg; William M Clemons; Ian Collinson; Yorgo Modis; Enno Hartmann; Stephen C Harrison; Tom A Rapoport Journal: Nature Date: 2003-12-03 Impact factor: 49.962
Authors: Karsten Schulmann; Frank E Brasch; Erdmute Kunstmann; Christoph Engel; Constanze Pagenstecher; Holger Vogelsang; Stefan Krüger; Tilman Vogel; Hanns-Peter Knaebel; Josef Rüschoff; Stephan A Hahn; Magnus V Knebel-Doeberitz; Gabriela Moeslein; Stephen J Meltzer; Hans K Schackert; Christiane Tympner; Elisabeth Mangold; Wolff Schmiegel Journal: Gastroenterology Date: 2005-03 Impact factor: 22.682
Authors: Richard B Lomax; Cristina Camello; Fabien Van Coppenolle; Ole H Petersen; Alexei V Tepikin Journal: J Biol Chem Date: 2002-05-06 Impact factor: 5.157
Authors: Yuriko Mori; Fumiaki Sato; Florin M Selaru; Andreea Olaru; Kellie Perry; Martha C Kimos; Gen Tamura; Nagahide Matsubara; Suna Wang; Yan Xu; Jing Yin; Tong-Tong Zou; Barbara Leggett; Joanne Young; Toshihiro Nukiwa; O Colin Stine; John M Abraham; David Shibata; Stephen J Meltzer Journal: Cancer Res Date: 2002-07-01 Impact factor: 12.701
Authors: Andreas Wirth; Martin Jung; Christiane Bies; Michael Frien; Jens Tyedmers; Richard Zimmermann; Richard Wagner Journal: Mol Cell Date: 2003-07 Impact factor: 19.328